

Corporate information as at 1 Feb 2017

ASX 300 company

ASX code: SPL

US OTCQX code: SPHRY

Share price: A\$0.76

Market capitalisation: ~A\$280M

Shares outstanding: 368.6M

Cash (at 31 Dec 2016): A\$36.3M

Average ASX daily volume: ~400K shares

Company contact information:

Address: 4-6 Southampton Cres, Abbotsford 3067, AUSTRALIA

Phone: (03) 8532 2700

Key contacts:

Jackie Fairley, CEO
+61 3 8532 2704
jackie.fairley@starpharma.com

Nigel Baade, CFO & Company Secretary
+61 3 8532 2704
nigel.baade@starpharma.com

Rebecca Wilson, Media & IR
WE Buchan
+61 3 8866 1200
rwilson@buchanwe.com.au

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a global biopharmaceutical company based in Australia with established commercial partnerships and products launched, or nearing commercial launch, across the pharmaceutical, sexual health and agrochemical sectors based on a proprietary dendrimer platform.

Investment Proposition

- **Unique proprietary dendrimer technology platform**
- **Product portfolio targeting three large, high value and diversified markets**
- **Proven track record of commercialisation, with the VivaGel® condom product in market & multiple late stage products under development**
- **Successful partnership strategy delivering results with several licencing deals and commercial arrangements in place, accelerating path to market and managing investment risk**
- **Well-funded, with existing cash reserves of \$36.3m**



VivaGel® condom: World's first and only antiviral Condom



- Condom lubricant contains VivaGel® which has been proven in laboratory studies to inactivate up to 99.9% of HIV, HSV and HPV, which are viruses that cause sexually transmitted infections (STIs)
- VivaGel® condom is available in Australia under Ansell's Lifestyles® Dual Protect™ brand, and regulatory approvals granted in Canada and New Zealand
- Licensed to Ansell, Okamoto (Japan), Koushan Pharmed (Iran) and Sky & Land (China - for the Government sector – annual government requirement: ~3 billion condoms)
- Advanced regulatory review in other markets; Canadian launch Q1 CY2017

VivaGel® BV: breakthrough products for bacterial vaginosis

VivaGel® formulated as a water-based gel and delivered vaginally – approved in Europe for topical treatment of bacterial vaginosis (BV) and now under Phase 3 clinical trials for the prevention of recurrent BV.

VivaGel® BV - treatment and symptomatic relief



- An acute use product, in an estimated market valued at >US\$750M globally
- Licensed to Aspen in Australia and New Zealand – 2017 product launch
- EU approval received – regulatory processes leveraging EU approval underway in multiple regions and commercial discussions with potential partners
- In 2017, granted Qualified Infectious Disease Product (QIDP) and Fast Track designation by the US FDA
- Extensive partnering discussions in several regions

Benefits of VivaGel® BV

- Rapid relief and resolution
- Non-antibiotic
- Not systemically absorbed
- Excellent tolerability
- Selective antimicrobial effect

Benefits of DEP®

- Improved efficacy
- Reduced toxicity
- Improved pharmacokinetics
- Improved solubility
- Patent life extension

Benefits of Priostar®

- Reduction of solvents – “greener” solutions
- Increased efficacy
- Formulation stability
- Solubility enhancement

VivaGel® BV – for prevention of recurrence

- Chronic use product, in an estimated market valued at >US\$1B globally
- Majority of BV sufferers experience recurrence – this is an unmet need with no approved products
- Phase 3 trials are fully enrolled - Special Protocol Assessment (SPA) from the US FDA (reduces regulatory risk for the clinical program)
- In 2017, granted Qualified Infectious Disease Product (QIDP) and Fast Track designation by the US FDA
- Results Q2 CY17 with NDA submission in preparation
- Extensive partnering discussions in several regions



DEP® drug delivery – revolutionary platform

Starpharma’s novel DEP® platform has broad commercial applicability in drug delivery by enhancing the performance and reducing toxicity of existing drugs as well as extending the patent life of existing or new drugs.

Partnered DEP® programs (partner funded)



Starpharma’s partnership with AstraZeneca includes a multiproduct DEP® licence which currently involves the development and commercialisation of two AstraZeneca oncology compounds with potential to add more. In July 2016, AstraZeneca initiated another new DEP® drug delivery program for a product in its portfolio - further validation of the value of Starpharma’s DEP® platform and its broad application to various products. Starpharma has also signed two Targeted DEP® partnerships with world leading antibody-drug conjugate companies.

“SPL estimates that each product successfully commercialised under this agreement could be worth around US\$450m to Starpharma and, depending on the range of indications and degree of commercial success in the market, potentially significantly more”

- Jackie Fairley Starpharma CEO

Internal DEP® programs

- DEP® docetaxel: enhanced version of anti-cancer drug Taxotere® - modified to remove the side effects of hair loss and white blood cell toxicity while retaining efficacy. Encouraging efficacy signals in a range of cancers emerging from the current Phase 1 trial, and will soon enter Phase 2.
- DEP® cabazitaxel: detergent free version of cancer drug Jevtana®. Significantly outperformed Jevtana® in a human breast cancer preclinical model with respect to both level and duration of anticancer activity and survival, and with superior safety.
- DEP® irinotecan: improved version of irinotecan showed enhanced tumour growth inhibition compared to irinotecan and near complete tumour regression in a human colon cancer mouse xenograft model.
- Targeted DEP®: Starpharma’s novel antibody-targeted DEP® conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model.



Priostar® Agrochemicals

Starpharma has development and commercialisation deals in the agrochemical sector with a number of major firms including Adama for 2,4-D and via its internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®) and glufosinate ammonium. Multiple commercial and product development catalysts are expected within next 12 months.

Starpharma’s Partners

